|
PTC Therapeutics, Inc. (PTCT) DCF Valoración
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
PTC Therapeutics, Inc. (PTCT) Bundle
¡Ahorre tiempo y mejore la precisión con nuestra calculadora DCF de PTC Therapeutics, Inc. (PTCT)! Equipado con datos reales de Apple y supuestos personalizables, esta herramienta le permite pronosticar, analizar y valorar PTC Therapeutics, Inc. (PTCT) como un inversor experimentado.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 307.0 | 380.8 | 538.6 | 698.8 | 937.8 | 1,241.3 | 1,643.0 | 2,174.6 | 2,878.3 | 3,809.7 |
| Revenue Growth, % | 0 | 24.04 | 41.45 | 29.75 | 34.2 | 32.36 | 32.36 | 32.36 | 32.36 | 32.36 |
| EBITDA | -191.4 | -297.0 | -374.4 | -367.8 | -330.3 | -739.1 | -978.3 | -1,294.8 | -1,713.8 | -2,268.4 |
| EBITDA, % | -62.34 | -78 | -69.52 | -52.63 | -35.22 | -59.54 | -59.54 | -59.54 | -59.54 | -59.54 |
| Depreciation | 36.1 | 49.6 | 71.5 | 128.8 | 236.6 | 202.9 | 268.5 | 355.4 | 470.4 | 622.6 |
| Depreciation, % | 11.75 | 13.02 | 13.28 | 18.44 | 25.23 | 16.34 | 16.34 | 16.34 | 16.34 | 16.34 |
| EBIT | -227.4 | -346.6 | -446.0 | -496.6 | -566.9 | -942.0 | -1,246.8 | -1,650.2 | -2,184.2 | -2,891.0 |
| EBIT, % | -74.09 | -91.02 | -82.8 | -71.07 | -60.45 | -75.89 | -75.89 | -75.89 | -75.89 | -75.89 |
| Total Cash | 686.6 | 1,103.7 | 773.4 | 410.7 | 876.7 | 1,122.8 | 1,486.1 | 1,967.0 | 2,603.5 | 3,445.9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 55.5 | 69.9 | 110.5 | 155.6 | 161.0 | 239.3 | 316.8 | 419.3 | 555.0 | 734.5 |
| Account Receivables, % | 18.09 | 18.37 | 20.51 | 22.27 | 17.17 | 19.28 | 19.28 | 19.28 | 19.28 | 19.28 |
| Inventories | 19.3 | 18.7 | 15.9 | 21.8 | 30.6 | 50.9 | 67.4 | 89.2 | 118.1 | 156.3 |
| Inventories, % | 6.28 | 4.91 | 2.94 | 3.12 | 3.26 | 4.1 | 4.1 | 4.1 | 4.1 | 4.1 |
| Accounts Payable | 10.3 | 18.7 | 23.0 | 27.3 | 6.0 | 42.4 | 56.2 | 74.3 | 98.4 | 130.2 |
| Accounts Payable, % | 3.36 | 4.9 | 4.28 | 3.9 | 0.64458 | 3.42 | 3.42 | 3.42 | 3.42 | 3.42 |
| Capital Expenditure | -45.4 | -56.0 | -85.3 | -152.5 | -120.6 | -198.7 | -263.0 | -348.0 | -460.7 | -609.7 |
| Capital Expenditure, % | -14.8 | -14.7 | -15.84 | -21.82 | -12.86 | -16.01 | -16.01 | -16.01 | -16.01 | -16.01 |
| Tax Rate, % | 9.98 | 9.98 | 9.98 | 9.98 | 9.98 | 9.98 | 9.98 | 9.98 | 9.98 | 9.98 |
| EBITAT | -238.5 | -376.9 | -450.7 | -472.5 | -510.3 | -914.0 | -1,209.8 | -1,601.3 | -2,119.4 | -2,805.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -312.4 | -388.7 | -497.9 | -543.0 | -429.8 | -972.1 | -1,284.5 | -1,700.1 | -2,250.2 | -2,978.4 |
| WACC, % | 6.77 | 6.77 | 6.77 | 6.66 | 6.54 | 6.7 | 6.7 | 6.7 | 6.7 | 6.7 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -7,327.8 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -3,038 | |||||||||
| Terminal Value | -64,596 | |||||||||
| Present Terminal Value | -46,700 | |||||||||
| Enterprise Value | -54,028 | |||||||||
| Net Debt | 1,635 | |||||||||
| Equity Value | -55,663 | |||||||||
| Diluted Shares Outstanding, MM | 75 | |||||||||
| Equity Value Per Share | -743.78 |
What You Will Get
- Real PTC Therapeutics Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for PTC Therapeutics, Inc. (PTCT).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates specific to PTC Therapeutics, Inc. (PTCT).
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on PTC Therapeutics, Inc. (PTCT)’s fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections for PTC Therapeutics, Inc. (PTCT).
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility for PTC Therapeutics, Inc. (PTCT).
Key Features
- Customizable Drug Development Parameters: Adjust essential inputs such as clinical trial timelines, market potential, and R&D expenditures.
- Real-Time Valuation Insights: Instantly computes intrinsic value, NPV, and other financial metrics.
- High-Precision Accuracy: Utilizes PTC Therapeutics’ actual financial data for credible valuation results.
- Streamlined Scenario Analysis: Effortlessly evaluate various assumptions and analyze different outcomes.
- Efficiency Booster: Remove the complexity of constructing detailed valuation models from the ground up.
How It Works
- Download: Obtain the pre-configured Excel file containing PTC Therapeutics, Inc.'s (PTCT) financial data.
- Customize: Modify projections, such as revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various forecasts and instantly compare results.
- Make Decisions: Utilize the valuation findings to inform your investment approach.
Why Choose PTC Therapeutics, Inc. (PTCT)?
- Innovative Solutions: Cutting-edge therapies designed to address unmet medical needs.
- Proven Results: Clinical trials demonstrate significant efficacy and safety profiles.
- Patient-Centric Approach: Focused on improving the quality of life for patients and their families.
- Expert Team: Led by industry professionals with extensive experience in biotechnology.
- Commitment to Research: Continuous investment in research and development for future advancements.
Who Should Use This Product?
- Investors: Assess PTC Therapeutics' (PTCT) fair value to inform investment choices.
- CFOs: Utilize a sophisticated DCF model for accurate financial reporting and analysis.
- Consultants: Easily modify the template for client valuation reports.
- Entrepreneurs: Discover financial modeling techniques employed by leading biotech firms.
- Educators: Employ it as a resource to teach valuation methods in finance courses.
What the Template Contains
- Comprehensive DCF Model: Editable template with detailed valuation calculations tailored for PTC Therapeutics, Inc. (PTCT).
- Real-World Data: PTC Therapeutics’ historical and projected financials preloaded for thorough analysis.
- Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage specific to PTC Therapeutics, Inc. (PTCT).
- Dashboard with Visual Outputs: Charts and tables designed for clear, actionable results related to PTC Therapeutics, Inc. (PTCT).